D-Index & Metrics Best Publications
Immunology
UK
2022

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 136 Citations 68,036 523 World Ranking 61 National Ranking 4
Medicine D-index 142 Citations 82,166 575 World Ranking 611 National Ranking 74

Research.com Recognitions

Awards & Achievements

2022 - Research.com Immunology in United Kingdom Leader Award

2020 - Distinguished Fellows of the American Association of Immunologists (AAI)

2014 - Canada Gairdner International Award

2010 - Member of the National Academy of Sciences

2008 - Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson for their role in the discovery of tumor necrosis factor-alpha, or TNF-alpha, as an effective therapeutic target for rheumatoid arthritis and other autoimmune diseases.

2006 - Fellow of the Royal Society, United Kingdom

Member of the Association of American Physicians

Member of the European Molecular Biology Organization (EMBO)

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cytokine
  • Immune system

Marc Feldmann spends much of his time researching Immunology, Tumor necrosis factor alpha, Rheumatoid arthritis, Cytokine and Arthritis. Immunology is a component of his Pathogenesis, Antigen, Antibody, Immune system and Monoclonal antibody studies. His studies examine the connections between Tumor necrosis factor alpha and genetics, as well as such issues in Receptor, with regards to Extracellular.

Marc Feldmann usually deals with Rheumatoid arthritis and limits it to topics linked to Autoimmunity and Human leukocyte antigen. His Cytokine research integrates issues from Proinflammatory cytokine, Inflammation, Synovial membrane and Autoimmune disease. His studies deal with areas such as Alpha and Ex vivo as well as Arthritis.

His most cited work include:

  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (2688 citations)
  • ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS (2251 citations)
  • Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (2178 citations)

What are the main themes of his work throughout his whole career to date?

Marc Feldmann mainly investigates Immunology, Tumor necrosis factor alpha, Antigen, Cytokine and Rheumatoid arthritis. His Immunology study frequently draws connections to adjacent fields such as Receptor. His Tumor necrosis factor alpha study integrates concerns from other disciplines, such as Cancer research, Clinical trial, Blockade, Necrosis and Pharmacology.

His biological study spans a wide range of topics, including In vitro, T cell, Antigen-presenting cell, Molecular biology and Cell biology. His work deals with themes such as Proinflammatory cytokine, Endocrinology and Synovial membrane, which intersect with Cytokine. Autoimmune disease is closely connected to Autoimmunity in his research, which is encompassed under the umbrella topic of Rheumatoid arthritis.

He most often published in these fields:

  • Immunology (57.85%)
  • Tumor necrosis factor alpha (25.58%)
  • Antigen (25.58%)

What were the highlights of his more recent work (between 2008-2021)?

  • Immunology (57.85%)
  • Tumor necrosis factor alpha (25.58%)
  • Inflammation (10.03%)

In recent papers he was focusing on the following fields of study:

Marc Feldmann mostly deals with Immunology, Tumor necrosis factor alpha, Inflammation, Rheumatoid arthritis and Cytokine. His Immunology study combines topics in areas such as Receptor and Internal medicine. His studies in Internal medicine integrate themes in fields like Gastroenterology and Endocrinology.

His work carried out in the field of Tumor necrosis factor alpha brings together such families of science as Cancer research, Necrosis, Postoperative cognitive dysfunction, Neuroinflammation and Fibrosis. His research on Rheumatoid arthritis also deals with topics like

  • Etanercept most often made with reference to Infliximab,
  • Fusion protein that connect with fields like Monoclonal antibody and Immunotherapy. His Cytokine course of study focuses on Histone and Mitochondrial biogenesis.

Between 2008 and 2021, his most popular works were:

  • IRF5 Promotes Inflammatory Macrophage Polarization and TH1-TH17 Responses (798 citations)
  • Role of interleukin-1beta in postoperative cognitive dysfunction. (464 citations)
  • Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. (440 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Immune system
  • Cytokine

The scientist’s investigation covers issues in Immunology, Tumor necrosis factor alpha, Inflammation, Cytokine and Arthritis. The study of Immunology is intertwined with the study of Receptor in a number of ways. His Tumor necrosis factor alpha research includes themes of NFKB1, Neuroinflammation, Cellular infiltration and Postoperative cognitive dysfunction.

His Inflammation study incorporates themes from Signal transduction, Cell type and Pneumonia. His study in Cytokine is interdisciplinary in nature, drawing from both Blockade, Antibody and FOXP3. His Arthritis research incorporates themes from Porphyromonas gingivalis, IRF5 and Transcription factor.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

P E Lipsky;D M van der Heijde;E W St Clair;D E Furst.
The New England Journal of Medicine (2000)

4752 Citations

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

R Maini;E W St Clair;F Breedveld;D Furst.
The Lancet (1999)

3606 Citations

ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS

Marc Feldmann;Fionula M. Brennan;Ravinder N. Maini.
Annual Review of Immunology (1996)

2974 Citations

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

M.J Elliott;R.N Maini;M Feldmann;J.R Kalden.
The Lancet (1994)

2091 Citations

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen.
Arthritis & Rheumatism (1998)

2076 Citations

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Marc Feldmann;Ravinder N. Maini.
Annual Review of Immunology (2001)

1660 Citations

ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY

G F Bottazzo;R Pujol-Borrell;T Hanafusa;M Feldmann.
The Lancet (1983)

1499 Citations

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Richard O. Williams;Marc Feldmann;Ravinder N. Maini.
Proceedings of the National Academy of Sciences of the United States of America (1992)

1264 Citations

IRF5 Promotes Inflammatory Macrophage Polarization and TH1-TH17 Responses

Thomas Krausgruber;Katrina Blazek;Timothy Smallie;Saba Alzabin.
Nature Immunology (2011)

1242 Citations

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

F M Brennan;D Chantry;A Jackson;R Maini.
The Lancet (1989)

1180 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Marc Feldmann

Paul Emery

Paul Emery

University of Leeds

Publications: 152

Paul P. Tak

Paul P. Tak

GlaxoSmithKline (United Kingdom)

Publications: 122

Iain B. McInnes

Iain B. McInnes

University of Glasgow

Publications: 105

Josef S. Smolen

Josef S. Smolen

Medical University of Vienna

Publications: 102

Tadamitsu Kishimoto

Tadamitsu Kishimoto

Osaka University

Publications: 82

Lars Klareskog

Lars Klareskog

Karolinska Institute

Publications: 80

Rikard Holmdahl

Rikard Holmdahl

Karolinska Institute

Publications: 79

Tsutomu Takeuchi

Tsutomu Takeuchi

Keio University

Publications: 77

Georg Schett

Georg Schett

University of Erlangen-Nuremberg

Publications: 69

Sergei A. Nedospasov

Sergei A. Nedospasov

Engelhardt Institute of Molecular Biology

Publications: 66

Alisa E. Koch

Alisa E. Koch

University of Michigan–Ann Arbor

Publications: 66

Wim B. van den Berg

Wim B. van den Berg

Radboud University Nijmegen

Publications: 64

Marie-Christophe Boissier

Marie-Christophe Boissier

Université Paris Cité

Publications: 64

Josef S. Smolen

Josef S. Smolen

University of Vienna

Publications: 61

Richard O. Williams

Richard O. Williams

University of Oxford

Publications: 61

Larry W. Moreland

Larry W. Moreland

University of Pittsburgh

Publications: 60

Trending Scientists

Franco Zambonelli

Franco Zambonelli

University of Modena and Reggio Emilia

Jonathan Le Roux

Jonathan Le Roux

Mitsubishi Electric (United States)

Francesco Marsili

Francesco Marsili

Facebook (United States)

Wei Zhang

Wei Zhang

Chinese Academy of Sciences

Philip J. Withers

Philip J. Withers

University of Manchester

Lori L. Bonnycastle

Lori L. Bonnycastle

National Institutes of Health

Stephan B. Munch

Stephan B. Munch

National Oceanic and Atmospheric Administration

John P. Carr

John P. Carr

University of Cambridge

Mark R. Denison

Mark R. Denison

Vanderbilt University Medical Center

Rainer Volkamer

Rainer Volkamer

University of Colorado Boulder

Markus Raab

Markus Raab

German Sport University Cologne

Raymond A. Noe

Raymond A. Noe

The Ohio State University

Nora S. Newcombe

Nora S. Newcombe

Temple University

Clinton T. Rubin

Clinton T. Rubin

Stony Brook University

Heikki V. Huikuri

Heikki V. Huikuri

Oulu University Hospital

Davis Jenkins

Davis Jenkins

Columbia University

Something went wrong. Please try again later.